Stryker

Stryker (NYSE:SYK) announced today that it launched the Insignia hip stem for total hip and hemiarthroplasty procedures.

Presenting at the American Academy of Orthopaedic Surgeons (AAOS) 2022 Annual Meeting in Chicago, Stryker introduced the Insignia hip stem for optimizing patient fit and surgeon ease of implantation in muscle-sparing approaches for total hip and hemiarthroplasty procedures.

Insignia has compatibility with Stryker’s Mako SmartRobotics platform utilizing Total Hip 4.1 software, allowing surgeons to use data from a 3D, CT-based plan to capture each patient’s unique anatomy, according to a news release.

The platform includes Tri-Stage broach featuring three different tooth geometries, along with unique, size-specific collar lengths and a range of femoral offsets for enhanced fit and function. Insignia also has a low-profile soldier, short stem lengths nad distal relief to ease lateralization and insertion during muscle-sparing …

Stryker (NYSE:SYK) announced today that it launched its new Prostep MICA Solo Guide for minimally invasive bunion procedures.

Kalamazoo, Michigan-based Stryker designed the Prostep MICA all-in-one procedure guide for use by a solo surgeon, potentially eliminating the need for additional surgical assistance during a minimally invasive bunion operation.

According to a news release, surgeons have traditionally conducted such procedures using a “freehand” technique that requires both of the surgeon’s hands to perform different tasks simultaneously. Stryker’s newly launched platform acts as a third hand for the surgeon, offering automatic targeting of the screw, stabilization of the head fragment and a controlled, adjustable shift.

Stryker said the Prostep MICA streamlines procedures to allow for reproducibility while minimizing the need for a surgical assistant.

Other features that Stryker’s platform offers when compared …

Stryker (NYSE:SYK) posted mixed fourth-quarter results, with the COVID-19 omicron variant pressuring elective procedure volumes in December.

The Kalamazoo, Michigan–based ortho device giant reported profits of $662 million, or $1.73 per share, on sales of $4.701 billion for the three months ended Dec. 31, 2021. The results, posted yesterday evening, represented a bottom-line gain of 16.5% and sales growth of 10.3% compared with Q4 2020.

Adjusted to exclude one-time items, earnings per share were $2.71, a penny behind The Street, where analysts were looking for EPS of $2.72 on sales of $4.61 billion.

Investor Relations VP Preston Wells told analysts yesterday evening that it wasn’t just omicron affecting procedure volumes: Ongoing nursing staffing shortages disrupted hospital scheduling. Hospital staffing challenges also delayed the installation of high-demand capital equipment from Stryker, and the company also had to grapple with raw materials sho…

Kalamazoo, Michigan-based Stryker touts its limited-market release, patient-matched primary reversed glenoid as the first surgeon-driven, primary patient-specific implant available in shoulder arthroplasty. The company planned the implant on its Blueprint 3D planning software.

According to a news release, Dr. Jay Keener of St. Louis completed the first implant on Jan. 13, 2022. It will be highlighted in a presentation at the 2022 Advanced Shoulder Arthroplasty (ASAP) Meeting on Jan. 21 in Snowbird, Utah.

“The patient-matched glenoid puts surgeons in the driver’s seat to contour the implant to the face of the native glenoid that is unique to each patient’s anatomy,” Dr. George S. Athwal, one of the designers of the implant system, said in the release. “The patient-matched glenoid system increases efficie…